Today: 7 February 2026
Subscribe
Browse Category

Drug Pricing News 30 December 2025 - 5 January 2026

Eli Lilly stock slides as Novo’s Wegovy pill hits U.S. shelves and stokes obesity-drug pricing fears

Eli Lilly stock slides as Novo’s Wegovy pill hits U.S. shelves and stokes obesity-drug pricing fears

New York, January 5, 2026, 10:58 (ET) — Regular session Eli Lilly and Company shares fell about 3.4% on Monday, extending early losses after rival Novo Nordisk began selling a pill version of its Wegovy weight-loss drug in the United States. The stock was down at $1,043.14 after dipping nearly 4% earlier in the session. The move puts the spotlight back on pricing power in obesity drugs, a market that has helped lift Lilly’s valuation and that investors treat as a multi-year growth engine. Novo said its once-daily Wegovy pill will start at $149 a month for self-paying patients, with
5 January 2026
·····
Eli Lilly stock today: LLY ticks higher as drug-price resets and a fresh upgrade sharpen focus

Eli Lilly stock today: LLY ticks higher as drug-price resets and a fresh upgrade sharpen focus

NEW YORK, January 3, 2026, 10:33 ET — Market closed Eli Lilly and Company shares closed up 0.53% at $1,080.36 on Friday and were down 0.17% in after-hours trading at $1,078.50. The move matters because early January is when many drugmakers reset “list prices” — the published prices before rebates and insurer discounts — and those changes can shape negotiations with payers. Policy pressure on drug costs has also intensified as the new year begins. For Lilly, pricing headlines can carry outsized weight. The company’s growth narrative is closely tied to high-demand diabetes and obesity medicines, leaving investors sensitive to
3 January 2026
·····
AbbVie stock edges up today as Linzess partner Ironwood cuts list price, lifts 2026 outlook

AbbVie stock edges up today as Linzess partner Ironwood cuts list price, lifts 2026 outlook

NEW YORK, Jan 2, 2026, 14:08 ET — Regular session AbbVie shares ticked higher on Friday after Ironwood Pharmaceuticals, its partner on constipation drug Linzess, raised its 2026 outlook and said it lowered the medicine’s list price at the start of the year. The update matters because Linzess is co-developed and co-commercialized with AbbVie in the U.S., and changes in pricing can shift how much revenue is left after rebates and discounts. It also lands as investors reopen the books for 2026 with drug pricing back on the agenda and macro data next week expected to reset interest-rate bets, a
2 January 2026
·····
Pfizer stock rises today as 2026 drug price hikes grab headlines again — what PFE investors are watching

Pfizer stock rises today as 2026 drug price hikes grab headlines again — what PFE investors are watching

NEW YORK, January 2, 2026, 13:56 ET — Regular session Pfizer Inc shares rose 0.8% to $25.09 on Friday, as investors digested renewed attention on U.S. drug pricing and early-year list-price changes. The timing matters. January is when drugmakers typically reset U.S. prices, and the moves can quickly become a political and regulatory flashpoint — especially as the Trump administration keeps pressing for lower costs. For Pfizer, pricing headlines also land as the company tries to stabilize revenue after pandemic-era demand faded. Investors are sensitive to anything that could trigger tougher scrutiny or force steeper discounts. List price is the
2 January 2026
·····
Pfizer stock slips before the bell as 2026 drug price hikes put PFE back in focus

Pfizer stock slips before the bell as 2026 drug price hikes put PFE back in focus

NEW YORK, Jan 2, 2026, 09:18 ET — Premarket Pfizer Inc shares fell 0.4% to $24.90 in premarket trading on Friday after a Reuters report said the drugmaker plans to raise U.S. list prices on around 80 medicines in 2026. Reuters The pricing moves matter now because January is when drugmakers typically reset U.S. list prices, a closely watched “sticker price” that can shape political scrutiny and payer negotiations. They also land as the Trump administration presses manufacturers to lower U.S. drug costs, putting any annual price round under a brighter spotlight than in prior years. A drug’s list price
2 January 2026
·····
Pfizer stock today: PFE slips as report flags 2026 U.S. drug price hikes

Pfizer stock today: PFE slips as report flags 2026 U.S. drug price hikes

NEW YORK, January 1, 2026, 20:51 ET — Market closed Pfizer Inc (PFE) shares last traded at $24.90, down 0.4% from the previous close, with U.S. markets closed on Thursday for the New Year’s Day holiday. Reuters reported Pfizer is leading a new round of U.S. list-price increases for 2026, planning hikes on around 80 drugs and vaccines — including a 15% rise for its COVID-19 shot Comirnaty — as drugmakers overall line up price increases on at least 350 branded medicines, with a median hike of about 4%. “They really just nibble around the margins,” said Dr. Benjamin Rome,
2 January 2026
·····
Eli Lilly stock ends 2025 lower as 2026 drug-price shifts and GLP-1 pill race come into focus

Eli Lilly stock ends 2025 lower as 2026 drug-price shifts and GLP-1 pill race come into focus

NEW YORK, January 1, 2026, 10:21 ET — Market closed Eli Lilly shares slipped 0.5% in Wednesday’s final session of 2025, closing at $1,074.68, before U.S. markets shut for the New Year’s Day holiday. StockAnalysis+1 Why it matters now: drugmakers typically reset U.S. list prices at the start of the year, and new data have put the industry’s pricing playbook back under a political microscope. Reuters reported drugmakers plan to raise list prices on at least 350 branded medicines in 2026, even as they cut prices on a handful of drugs. Reuters Lilly sits at the center of two investor
1 January 2026
····
Pfizer stock in focus on New Year’s Day after report of 2026 U.S. drug price hikes

Pfizer stock in focus on New Year’s Day after report of 2026 U.S. drug price hikes

NEW YORK, January 1, 2026, 06:48 ET — Market closed Pfizer Inc shares were last indicated slightly lower after hours on Wednesday after a report said the drugmaker plans to raise U.S. list prices on about 80 medicines in 2026. U.S. stock markets were closed on Thursday for the New Year’s Day holiday. (Reuters) Why it matters now: January is the industry’s main reset point for annual drug pricing, and the moves land as Washington keeps drug costs in the political crosshairs. Investors often read fresh price actions as both a revenue lever and a regulatory risk flag. The headline
1 January 2026
·····
Pfizer stock dips after-hours as 2026 drug price hike list puts PFE in the spotlight

Pfizer stock dips after-hours as 2026 drug price hike list puts PFE in the spotlight

NEW YORK, December 31, 2025, 18:50 ET — After-hours Pfizer Inc. shares fell about 0.4% to $24.90 in after-hours trading on Wednesday, after a report said the drugmaker is leading a wave of U.S. list-price increases set for 2026. The data, compiled by healthcare research firm 3 Axis Advisors, showed drugmakers plan hikes on at least 350 branded medicines, with Pfizer accounting for around 80 increases, including a 15% rise for its COVID vaccine Comirnaty. “They really just nibble around the margins,” said Dr. Benjamin Rome, a health policy researcher at Brigham and Women’s Hospital in Boston. Reuters The timing
1 January 2026
·····
Pfizer stock today: PFE slips after report on 2026 U.S. drug price hikes

Pfizer stock today: PFE slips after report on 2026 U.S. drug price hikes

NEW YORK, December 31, 2025, 14:53 ET — Regular session Pfizer shares were down 0.1% at $24.96 in afternoon trade on Wednesday after a Reuters report said the drugmaker plans U.S. list-price hikes on about 80 medicines in 2026. Reuters The planned increases, set to start Jan. 1, land at a sensitive moment for drug pricing as the Trump administration presses the industry to lower costs. Annual list-price resets can also shape negotiations with insurers and the political risk premium investors apply to large drugmakers. Pfizer’s own outlook has put a spotlight on revenue durability. In its December guidance, Pfizer
31 December 2025
·····
Pfizer stock flat before the bell as report flags 2026 U.S. drug price hikes, including 15% Comirnaty rise

Pfizer stock flat before the bell as report flags 2026 U.S. drug price hikes, including 15% Comirnaty rise

NEW YORK, December 31, 2025, 08:51 ET — Premarket Pfizer Inc shares were little changed in premarket trading on Wednesday after a report showed the drugmaker is leading a new round of U.S. list-price increases for 2026. The stock was down about 0.02% at $24.99, after closing Tuesday at roughly $25.00. The issue matters now because drug pricing has returned to the front burner in Washington, with the Trump administration pressing manufacturers to rein in costs. Year-end is also when many companies set list-price changes that typically take effect in early January. For investors, higher list prices can support revenue
31 December 2025
·····
Novo Nordisk halves Wegovy prices in parts of China as copycat competition looms

Novo Nordisk halves Wegovy prices in parts of China as copycat competition looms

NEW YORK, December 29, 2025, 22:14 ET Novo Nordisk said it is lowering prices of its top-selling obesity drug Wegovy in China, after local outlet Yicai reported that list prices for the two highest doses were cut by 48% in the southwestern provinces of Yunnan and Sichuan. The new monthly list prices were 987 yuan ($141) and 1,284 yuan, Yicai said, citing local procurement authorities. Reuters The price move matters because China is fast becoming a pivotal growth market for weight-loss medicines, and pricing is now moving to the center of competition. Drugmakers are trying to lock in patients and
30 December 2025
····
1 2 3 4

Stock Market Today

Seagate (STX) stock jumps nearly 6% as Citi hikes target — what to watch next week

Seagate (STX) stock jumps nearly 6% as Citi hikes target — what to watch next week

7 February 2026
Seagate shares rose 5.9% to $429.32 Friday after Citigroup raised its price target to $480 and reiterated a buy rating. The gain ended a two-day slide but left the stock 6.6% below its Feb. 3 high. CEO Dave Mosley sold 20,000 shares on Feb. 2 under a pre-arranged plan, SEC filings show. U.S. jobs and inflation data next week are seen as key tests for tech stocks.
Cummins (CMI) stock price rebounds after earnings whipsaw as investors eye data-center power demand

Cummins (CMI) stock price rebounds after earnings whipsaw as investors eye data-center power demand

7 February 2026
Cummins shares jumped 6.8% to $577.73 Friday, recovering from a nearly 9% post-earnings drop the day before. The company reported Q4 revenue up 1% to $8.54 billion, took a $218 million charge tied to its hydrogen business, and guided for 2026 EBITDA of 17–18% of sales. Demand for data center generators offset weakness in North American truck markets. Analyst reaction was mixed; Truist raised its price target.
Corning stock hits first record close since 2000 as jobs, CPI data loom

Corning stock hits first record close since 2000 as jobs, CPI data loom

7 February 2026
Corning shares surged 8.3% to $122.16 Friday, their highest close since the dot-com era, after Meta agreed to buy up to $6 billion in fiber-optic cables. The stock is up 40% since late 2025, fueled by strong first-quarter guidance and AI data-center demand. Insiders sold shares following the rally, SEC filings show. Investors await next week’s U.S. jobs and inflation data for rate signals.
Go toTop